Quintiles maintains 'outperform' rating following recent flurry of activity

By Dan Stanton contact

- Last updated on GMT

Related tags: Asia-pacific

A new Asia-Pacific market access service and the acquisition of Japanese CRO Clio Science has helped bolster Quintiles' investment desirability
A new Asia-Pacific market access service and the acquisition of Japanese CRO Clio Science has helped bolster Quintiles' investment desirability
A recent spate of activity - including the acquisition of a Japanese CRO and a secondary equity offering - has boosted Quintiles’ investment appeal, an analyst says.

The world’s largest contract research organisation (CRO) Quintiles has had a busy few weeks:

Last week it announced it has fully acquired Clio Science, a full-service CRO with a staff of 70 based in Tokyo and Osaka. Also this month, Quintiles opened a new bioanalytical lab in the Netherlands​ and, on the financial side,  secured almost $2bn (€1.8bn)​ following the completion of a refinancing programme.

“While none of these events has a major impact on our model, we have updated our estimates to reflect the flurry of activity,”​ William Blair analyst John Kreger said in a note.

“We maintain our Outperform rating on Quintiles given strong bookings and a more attractive valuation of late, and continue to view Quintiles as the most diversified way to invest in late-stage pharma outsourcing.”

Asia-Pacific market access

In its latest announcement, Quintiles is launching a new service for emerging biopharma companies in the Asia-Pacific region, based on its estimation that there are over 1,400 such firms across the region looking for help accessing the regional and global markets.

“We work with all sized companies but smaller emerging biopharma companies have a number of regulatory and access challenges and needs that need to be addressed,”​ Quintiles spokesman Jay Johnson told Outsourcing-Pharma.com.

“Other CROs do offer these services but what we did was take a look at the services that we had across our network in 13 Asia-Pacific countries and decided this new solution set would work best.”

The service includes dedicated local project leadership in the region, offering knowledge of local markets, customs and language, and accelerated patient recruitment due to the firm’s global and Asia-Pacific network.

Related news

Related products

show more

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 26-Jul-2021 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Adapting supply chains to new ways of working

Adapting supply chains to new ways of working

World Courier | 15-Jul-2021 | Technical / White Paper

COVID-19 has changed the way we operate. We have adapted our supply chain solutions to meet our clients’ requirements while following World Courier standard...

Empowering Clinical Trial Sponsors with Analytics

Empowering Clinical Trial Sponsors with Analytics

PerkinElmer | 14-Jul-2021 | Technical / White Paper

Is your Clinical Data Review creating problems or solving them? Take Control of Your Data. PerkinElmer Informatics Clinical Solutions, powered by Tibco...

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 09-Jun-2021 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Related suppliers

Follow us

Products

View more

Webinars